Herceptin Research Today is a free monthly online journal that collates and summarizes the latest research about Herceptin, including details on side-effects, breast cancer, treatment, therapy.

Volume 4 (2007), Issue 3 (March)

1. Synthetic affibody molecules: a novel class of affinity ligands for molecular imaging of HER2-expressing malignant tumors.
   Cancer Res, 67(5): 2178-86. [Abstract] [Full-text]
2. Tissue microarray technology in breast cancer HER2 diagnostics.
   Pathol Res Pract, 203(3): 169-77. [Abstract] [Full-text]
3. Selection of chemotherapeutic drugs in adjuvant programs based on molecular profiles: where do we stand?
   Crit Rev Oncol Hematol, 62(1): 1-8. [Abstract] [Full-text]
4. Ipsilateral breast carcinoma following treatment for primary breast lymphoma.
   Onkologie, 30(3): 134-6. [Abstract] [Full-text]
5. Amrubicin, a novel 9-aminoanthracycline, enhances the antitumor activity of chemotherapeutic agents against human cancer cells in vitro and in vivo.
   Cancer Sci, 98(3): 447-54. [Abstract] [Full-text]
6. Molecular-based choice of cancer therapy: realities and expectations.
   Clin Chim Acta, 379(1): 1-13. [Abstract] [Full-text]
7. Modulation of cancer cell survival pathways using multivalent liposomal therapeutic antibody constructs.
   Mol Cancer Ther, 6(3): 844-55. [Abstract] [Full-text]
8. Molecular cloning of hMena (ENAH) and its splice variant hMena+11a: epidermal growth factor increases their expression and stimulates hMena+11a phosphorylation in breast cancer cell lines.
   Cancer Res, 67(6): 2657-65. [Abstract] [Full-text]
9. Potentiation of high-LET radiation by gemcitabine: targeting HER2 with trastuzumab to treat disseminated peritoneal disease.
   Clin Cancer Res, 13(6): 1926-35. [Abstract] [Full-text]
10. A nonfucosylated anti-HER2 antibody augments antibody-dependent cellular cytotoxicity in breast cancer patients.
    Clin Cancer Res, 13(6): 1875-82. [Abstract] [Full-text]
11. Challenges for patient selection with VEGF inhibitors.
    Cancer Chemother Pharmacol. [Abstract] [Full-text]
12. HER-2/neu overexpression is an independent prognostic factor in colorectal cancer.
    Int J Colorectal Dis, 22(5): 491-7. [Abstract] [Full-text]
13. Antitumor activity of trastuzumab in combination with chemotherapy in human gastric cancer xenograft models.
    Cancer Chemother Pharmacol, 59(6): 795-805. [Abstract] [Full-text]
14. Adjuvant treatment of breast cancer: impact of monoclonal antibody therapy directed against the HER2 receptor.
    Expert Opin Biol Ther, 7(4): 487-91. [Abstract] [Full-text]
15. Results from an observational trial with oral vinorelbine and trastuzumab in advanced breast cancer.
    Breast Cancer Res Treat, 102(3): 375-81. [Abstract] [Full-text]
16. Vinorelbine plus 3-weekly trastuzumab in metastatic breast cancer: a single-centre phase 2 trial.
    BMC Cancer, 7: 50. [Abstract] [Full-text]
17. A modified approach for I-FISH evaluation of ERBB2 (HER-2) gene copy numbers in breast carcinomas: comparison with HER-2/CEP17 ratio system.
    J Cancer Res Clin Oncol, 133(5): 321-9. [Abstract] [Full-text]
18. High-resolution genomic profiles of breast cancer cell lines assessed by tiling BAC array comparative genomic hybridization.
    Genes Chromosomes Cancer, 46(6): 543-558. [Abstract] [Full-text]

© 2004-2008 Herceptin Research Today. All Rights Reserved.